Massachusetts General Hospital Cancer Center Takes Delivery of a Helicos(TM) Genetic Analysis System

Back To Press & Events

Cambridge, MA - Aug 13, 2009 - Helicos BioSciences Corporation (NASDAQ: HLCS), a life science company focused on innovative genetic analysis technologies, today announced the placement of a Helicos(TM) Genetic Analysis System at the Massachusetts General Hospital (MGH) Cancer Center in the laboratory of Daniel Haber, MD, PhD.

"Mass General is an ideal setting for the demonstration of our single molecule sequencer's unique features and benefits" stated Ron Lowy, Helicos Chief Executive Officer.


The Helicos Genetic Analysis System is the world's first and only commercially available, single molecule sequencing technology, and enables scientists to conduct revolutionary studies in the fields of genome biology, cancer research, common diseases, and microbiology without DNA ligation or amplification. Genetic analysis with Helicos's technology eliminates the biases, complexity and errors introduced by DNA amplification, requires minute amounts of starting material, and provides the most direct and accurate view of biological samples.


"We are very excited to be working with the distinguished group led by Dr. Haber" stated Patrice Milos, Chief Scientific Officer of Helicos. "We expect great synergies for cancer research and diagnostics with the combination of two powerful technologies - the MGH's revolutionary circulating tumor cell microchip (CTC-chip) and Helicos's single molecule genetic analysis system".

Share On Twitter Linkedin